Progress in the prevention of cytomegalovirus infection after allogeneic bone marrow transplantation
Affiliations
- PMID: 8177726
Item in Clipboard
Progress in the prevention of cytomegalovirus infection after allogeneic bone marrow transplantation
Nouv Rev Fr Hematol (1978).
1994.
Abstract
There has been substantial progress in preventing and treating CMV infection. Prophylaxis with CMV screened blood products, IVIG and antiviral drugs (high dose acyclovir and/or Ganciclovir) considerably reduce the incidence of CMV disease and nearly eliminate CMV pneumonia after allogeneic BMT.
Similar articles
-
Prevention and treatment of cytomegalovirus infection and disease after bone marrow transplantation in the 1990s.Bone Marrow Transplant. 1991 Jul;8(1):7-11. Bone Marrow Transplant. 1991. PMID: 1655140 Review.
-
Prevention of cytomegalovirus infection following bone marrow transplantation: a randomized trial of blood product screening.Bone Marrow Transplant. 1991 Mar;7(3):227-34. Bone Marrow Transplant. 1991. PMID: 1647829 Clinical Trial.
-
Comparison of cytomegalovirus antigenemia and shell vial culture in allogeneic marrow transplantation recipients receiving ganciclovir prophylaxis.Bone Marrow Transplant. 1997 Jan;19(1):37-41. doi: 10.1038/sj.bmt.1700612. Bone Marrow Transplant. 1997. PMID: 9012929
-
Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.Bone Marrow Transplant. 1996 Apr;17(4):589-93. Bone Marrow Transplant. 1996. PMID: 8722360 Clinical Trial.
-
Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation.Haematologica. 1999 Jan;84(1):71-9. Haematologica. 1999. PMID: 10091394 Review.